Resource includes position statement and benefit design considerations for anti-obesity medications including GLP-1s WASHINGTON, Feb. 27, 2024 /PRNewswire/ — Obesity affects more than 40% of the US population with far-reaching consequences for not only individuals but employers grappling…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.